Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha ClinicAlpha Clinic ContactTrial SponsorDisease IndicationClinical Trial NameStatus of EnrollmentLearn More
City of Hope
Mihaela Cristea, MD
626-218-9200
mcristea@coh.org
Torque Therapeutics, Inc. Cancer - Lymphoma TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas Recruiting
City of Hope
Erminia Massarelli, MD
626-218-9200
emassarelli@coh.org
Atara Bio. Cancer - Nasopharyngeal Carcinoma Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) No longer active
City of Hope
Tanya Dorff, MD
626-218-9200
tdorff@coh.org
City of Hope Cancer - Prostate PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Recruiting
City of Hope
Myo Htut, MD
626-218-2405
mhtut@coh.org
Janssen Research & Development, LLC. Cancer - Myeloma A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1) Recruiting
City of Hope
Karen Reckamp, MD
626-218-9200
kreckamp@coh.org
Glaxo Smith Kline (GSK) Cancer - Lung Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab Recruiting
City of Hope
Leslie Popplewell, MD
626-218-2405
lpopplew@coh.org
Novartis Pharmaceuticals Cancer - Lymphona Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) Recruiting
City of Hope
Anthony Stein, MD
626-218-2405
stein@coh.org
Precision BioSciences, Inc. Cancer - Lymphoma Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL Recruiting
City of Hope
Alex Herrera, MD
626-218-2405
aherrera@coh.org
Kite Pharma Cancer - Lymphoma Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) Recruiting
City of Hope
Elizabeth Budde, MD, PhD
626-218-2405
ebudde@coh.org
City of Hope Cancer - Lymphoma Angiocrine: HuVEC infusion post HCT in lymphoma (Budde) Recruiting
City of Hope
Cheryl De Guzman
626-218-5613
CDeGuzman@coh.org
Children’s Hospital Los Angeles Infection After Stem Cell Transplant Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Recruiting
City of Hope
Fatemeh Bidmeshki
626-218-9393
fbidmeshki@coh.org
City of Hope Cancer - Brain HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases Recruiting
City of Hope
Joseph Rosenthal, MD
626-256-4673 ext 88442
jrosenthal@coh.org
City of Hope Sickle Cell Disease Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO) Recruiting
City of Hope
Myo Htut, MD
626-218-2405 ext 82405
mhtut@coh.org
Juno Therapeutics Cancer - Myeloma Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE) Recruiting
City of Hope
Behnam Badie, MD;
626-256-4673
bbadie@coh.org
City of Hope Cancer - Brain Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma Recruiting
City of Hope
Elizabeth Budde, MD
626-218-2405
Kite Pharma Cancer - Lymphoma A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma Recruiting
City of Hope
Rie Miyahira
626-256-4673 ext 80032
rmiyahira@coh.org
Angiocrine Bioscience Cancer - Leukemia A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation Recruiting
City of Hope
Lucy Ghoda
626-218-3605
lghoda@coh.org
City of Hope Neurodegenerative Disorder Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies Recruiting
City of Hope
Cara Nolan
626-218-3241
canolan@coh.org
Juno Therapeutics Cancer - Lymphoma An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) Recruiting
City of Hope
Teresa Kim
626-218-0263
teresakim@coh.org
City of Hope Sickle Cell Disease A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant Recruiting
City of Hope
Hormoz Babaei Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Celgene Cancer - Lymphoma An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) Recruiting
City of Hope
Hormoz Babaei Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Adaptimmune Cancer - Myeloma NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma Recruiting
City of Hope
Nadia Ewing, MD
(626) 256-4673 x89200
newing@coh.org
Sangamo Therapeutics Hemophilia A Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A Recruiting
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Leukemia Long-Term Follow-up Study for Patients Previously Treated With JCAR015 No longer active
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Leukemia Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) No longer active
City of Hope
Erminia Massarelli
626-218-9200
emassarelli@coh.org
Tessa Therapeutics Cancer - Nasopharyngeal Carcinoma A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngea Recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1) Recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) Active, not recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) No longer active
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Lymphoma Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) Recruiting
City of Hope
Nadia Ewing, MD
(626) 256-4673 x89200
​newing@coh.org
Sangamo Therapeutics Hemophilia B Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B Recruiting
City of Hope
Warren Chow, MD
(626) 256-4673 x89200
wchow@coh.org
Adaptimmune Cancer - Sarcoma A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma Active, not recruiting
City of Hope
Mihaela Cristea, MD
(626) 256-4673 x89200
mcristea@coh.org
Adaptimmune Cancer - Ovarian A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
City of Hope
L. Elizabeth Budde, MD, PhD
(626) 256-4673
ebudde@coh.org
City of Hope Cancer - Leukemia Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
City of Hope
Behnam Badie, MD
(626) 256-4673 ext 60098
bbadie@coh.org
City of Hope Cancer - Brain Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Recruiting
City of Hope
Amrita Krishnan, MD
(626) 256-4673 ext 62405
AKrishnan@coh.org
City of Hope Cancer - Lymphoma (AIDS-Related) Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Recruiting
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Active, not recruiting
City of Hope & UCLA
City of Hope: Amrita Krishnan, MD
(626) 256-4673 ext 62405
AKrishnan@coh.org

UCLA: Maricella Gonzalez
310-557-3729
mmgonzalez@mednet.ucla.edu
City of Hope HIV/AIDS Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Atara Bio Hematologic Malignancies An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
AlloVir Kidney transplant Phase 2 multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant recipients with Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Autolus Acute Lymphoblastic Leukaemia An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia Recruiting
UC Davis & UCSD
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Viacyte Type 1 diabetes An Open-Label, First-in-Human, Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects with Type 1 Diabetes Mellitus and Hypoglycemia Unawareness Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@hotmail.com
Capricor Therapeutics COVID A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients with Severe COVID-19 No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Eureka Therapeutics Hepatocellular Carcinoma An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Cabaletta Pemphigus Vulgaris Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects with Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Capricor Therapeutics Duchenne Muscular Dystrophy Open-Lael Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial (HOPE-2-OLE) Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Orca Biosystems Inc. Hematologic Malignancies A Study of Engineered Donor Grafts (TregGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Recruiting
1 2 3

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials. If you or a family member is interested in participating in a clinical trial, please visit clinicaltrials.gov to find a trial near you.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News